FDA rejects lorcaserin
Links shared publicly online about this topic.
- 773total visits
FDA rejects lorcaserin
View full resource at endocrinetoday.com
Tags: Obesity Medication, Drug, FDA, Lorcaserin
Most Recently Shared on October 26, 2010 at 2:28 pm By:
Weight loss pill Qnexa wins panel vote and awaits approval
news-medical.net — “The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.” View full resource at news-medical.net
Most Recently Shared on April 5, 2012 at 11:08 pm By:
Diet News: Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the ... http://t.co/rGbONdEq
Medical News:%20FDA Rejects BPA Ban - in Public Health & Policy, Public Health from MedPage Today
medpagetoday.com — “Medical News:%20FDA Rejects BPA Ban - in Public Health & Policy, Public Health from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on April 5, 2012 at 4:09 pm By:
Dr Joe's DIY Health is
founded on the principle that your health is directly influenced by how
you live your life. The decisions and choices you make about what you
put into your body, how active you are, how much rest and relaxation you
get and how you deal with stress impact on your health, vitality and wellbeing.
My
media activities include being a regular columnist in the West
Australian Newspaper, Guest reporter on Channel 7's Today/Tonight, radio
6PR mornings with Paul Murray and I am also their night line doctor. I
am on the advisory panel and contributor to Prevention Magazine, and am
spokesperson for Virtual Medical Centre.
In addition to this many of my articles are reproduced on other
websites and I am routinely sought for comment on health matters." /> Dr Joe Kosterich Doctor, Physician, and Active Health Library
FDA Rejects BPA Ban http://t.co/byyrSvs1 Wonder why? Something to do with $$$ ?
New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com
usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?” View full resource at usatoday.com
Most Recently Shared on April 4, 2012 at 10:45 pm By:
Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/YjlUT7Bn
FDA Rejects Call to Ban BPA in Food Containers - WSJ.com
online.wsj.com — “The FDA said it lacks the scientific information to ban the chemical bisphenol A from being used in food containers.” View full resource at online.wsj.com
Most Recently Shared on March 30, 2012 at 11:34 pm By:
FDA Rejects Call to Ban Chemical BPA http://t.co/FE8seW5u
FDA rejects call to ban BPA from food packaging - BusinessWeek
businessweek.com — “The Food and Drug Administration has rejected a petition from environmentalists that would have banned the plastic-hardening chemical bisphenol-A from all food and drink packaging, including plastic bottles and canned food.” View full resource at businessweek.com
Most Recently Shared on March 30, 2012 at 9:59 pm By:
Ari Brown Physician, Doctor, and Pediatrician
FDA says they won't ban BPA from food packaging. There is not enough evidence of adverse health effects. Research... http://t.co/t4sYJ8La
preview
emailactivity.ecn5.com — “preview” View full resource at emailactivity.ecn5.com
Most Recently Shared on March 29, 2012 at 6:00 pm By:
PharmaLive Pharma and Health News
#FDA Rejects Northera, Wants More Data http://t.co/9mMjNIYU #DailyAdvantage
ODAC rejects ridaforolimus as maintenance therapy for sarcoma | HemOncToday
hemonctoday.com — “An FDA panel rejected ridaforolimus as a maintenance therapy for patients with soft-tissue or bone ” View full resource at hemonctoday.com
Most Recently Shared on March 21, 2012 at 5:10 pm By:
HemOnc Today Oncology and Health News
ODAC rejects ridaforolimus as maintenance therapy for sarcoma: http://t.co/wgR3AMi1
FDA panel backs Glaxo drug for rare cancer | ajc.com
ajc.com — “WASHINGTON — A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease.” View full resource at ajc.com
Most Recently Shared on March 21, 2012 at 4:29 pm By:
Tom Heston, MD Physician, Doctor, and Family Medicine Doctor
FDA panel backs Glaxo drug for rare cancer - Atlanta Journal Constitution http://t.co/p4jwFZcO #medicine
FDA Backs Glaxo Drug For Rare Cancer | ThirdAge
thirdage.com — “ A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at thirdage.com
Most Recently Shared on March 21, 2012 at 12:19 am By:
FDA Backs Glaxo Drug For Rare Cancer http://t.co/QMfj2u64
FDA Panel Rejects Proposed Merck Cancer Drug For Sarcoma Patients
nasdaq.com — “NASDAQ News: FDA Panel Rejects Proposed Merck Cancer Drug For Sarcoma Patients” View full resource at nasdaq.com
Most Recently Shared on March 20, 2012 at 9:46 pm By:
FDA Panel Rejects Proposed Merck Cancer Drug For Sarcoma Patients: FDA Panel Rejects Proposed Merck Cancer Drug ... http://t.co/ZTW7ZLZe
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 6:57 pm By:
FDA panel backs Glaxo drug for rare sarcoma cancer: A panel of cancer experts voted against an experimental Merc... http://t.co/CS4hfxkn
FDA Panel Rejects Merck Drug for Sarcoma, but Backs Glaxo's Votrient - WSJ.com
online.wsj.com — “A federal advisory panel rejected an experimental Merck & Co. drug for use in patients with soft-tissue or bone sarcomas—on concerns that it didn't work well enough to offset potentially serious side effects—while backing a different drug from GlaxoSmithKline.” View full resource at online.wsj.com
Most Recently Shared on March 20, 2012 at 5:37 pm By:
FDA Panel Backs Glaxo Drug for Sarcoma http://t.co/Cc9B6D9P
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 5:29 pm By:
HealthTrendster Health Executive
FDA panel backs Glaxo drug for rare sarcoma cancer - A panel of cancer experts has backed the benefits of a GlaxoSmi... http://t.co/k7JJ13Oc
FDA Rejects 'Son Of Vytorin' - Forbes
forbes.com — “The FDA seems to want more data on how Merck formulated its pills.” View full resource at forbes.com
Most Recently Shared on March 5, 2012 at 7:46 pm By:
FDA panel backs previously rejected Vivus obesity pill - USATODAY.com
yourlife.usatoday.com — “The FDA panel of outside physicians voted 20-2 in favor of the weight loss drug Qnexa.” View full resource at yourlife.usatoday.com
Most Recently Shared on February 22, 2012 at 10:02 pm By:
FDA panel backs previously rejected obesity pill http://t.co/7rw6Xo2v
Advertisement
